Effect of subconjunctival Bevacizumab injection on the outcome of Ahmed glaucoma valve implantation: a randomized control trial

Importance The effect of subconjunctival Bevacizumab injection on the outcome of Ahmed glaucoma valve (AGV) implantation. Background Evaluation of efficacy and safety of subconjunctival Bevacizumab injection adjunctive to AGV implantation. Design Prospective and randomized clinical trial. Participan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & experimental ophthalmology 2018-09, Vol.46 (7), p.750-756
Hauptverfasser: Miraftabi, Arezoo, Nilforushan, Naveed, Darghahi, Mina, Alemzadeh, Sayyed Amirpooya, Parsamanesh, Mohammad, Yadgari, Maryam
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Importance The effect of subconjunctival Bevacizumab injection on the outcome of Ahmed glaucoma valve (AGV) implantation. Background Evaluation of efficacy and safety of subconjunctival Bevacizumab injection adjunctive to AGV implantation. Design Prospective and randomized clinical trial. Participants Fifty eyes of 50 patients with diagnosis of glaucoma that were candidate for AGV surgery were included. Methods In 25 eyes, conventional AGV surgery (group 1) and in 25 eyes AGV surgery with subconjunctival Bevacizumab (group 2) was performed by block randomization Main Outcome Measures The primary outcome measure was surgical success. Outcome measures were compared at postoperative month 3, 6 and 12. Results Mean age of patients was 58.76 ± 12.11 and 51.36 ± 15.44 years in group 1 and 2 respectively (P = 0.06). Mean intraocular pressure (IOP) at baseline was 24.88 ± 7.62 mmHg in group 1 and 27.52 ± 8.57 mmHg in group 2 which decreased to15.4 ± 4.4 mmHg in group 1 and 13.42 ± 2.9 mmHg in group 2 (P < 0.00) at last follow up. Surgical success was defined in two level: postoperative IOP ≤ 21 mmHg with at least 20% reduction in IOP (Criterion A), either with no medication (complete success) or with no more than two medications (qualified success) and criterion B with the same definition but the IOP ≤ 18 mmHg The cumulative success according to criterion A and B was 77.8%, 72.2% in group 1 and 89.5% in group 2, respectively, at the end of follow‐up. Conclusions and Relevance Subconjunctival injection of Bevacizumab adjunctive to AGV implantation leads to higher success rate compared with AGV alone in one year follow‐up.
ISSN:1442-6404
1442-9071
DOI:10.1111/ceo.13191